Posts tagged “GSK”
GSK recommended withdrawing the article, published in 2010, after concluding an investigation in June that found some data had been misrepresented, London-based Glaxo said in a statement Friday. Five of the named authors, including the head of its Chinese research and development, resigned or were fired following the probe.
The Triangle's two major cancer centers didn't make the list, but GSK lines up six other major global research institutions to collaborate on research into new ways to fight cancer using a mix of drugs. It's the "new wave" of research, a GSK spokesperson says.
U.K. Prime Minister David Cameron defended GlaxoSmithKline over bribery allegations in China, saying the British drugmaker is an important and strong business. Cameron has been joined by GSK CEO Andrew Witty on his trade mission to China this week.
GlaxoSmithKline's Chief Executive Officer Andrew Witty is with U.K. Prime Minister David Cameron as part of a trade mission to China as his company faces an investigation in the country. In other news: Head of GSK vaccines group to become CEO of Japanese pharmaceutical firm.
The Food and Drug Administration reviewed independent researchers' reanalysis of a Glaxo study, called Record, that confirmed Avandia doesn't raise the risk of death, heart attack or stroke. Avandia's reign atop the diabetes market as a $3 billion-a-year medicine began to end after a 2007 New England Journal of Medicine article found a 43 percent increased risk of heart attack in patients taking the drug in a combination of results from smaller studies. Duke University reanalyzed Avandia data.
The Food and Drug Administration cleared the vaccine for H5N1 influenza for use in people 18 years of age and older at increased risk of exposure to the virus, the agency said Friday in a statement. Bird flu has caused serious illness and death outside of the U.S. mainly among people who come in close contact with infected and ill poultry.
"Aspen's shares have risen well, so Glaxo has made fairly good money," an analyst says. "This doesn't seem to indicate a change in relationship between them, rather it's probably a good time to take the profit."
Berkshire Hathaway has sold shares in GlaxoSmithKline as well as Sanofi as Warren Buffett's company joined investors who have soured on the European drugmakers since their stocks reached highs in May.
When 100 of the top lung doctors in the U.S. gathered in Houston recently to learn about GlaxoSmithKline's new respiratory drug, one message rang loud and clear: Don't ignore the pneumonia risk. It's part of a new "Patient First" strategy from GSK.
Charges against individual executives rather than the company would be GSK's preferred outcome. Charges against the company could result in large fines and possibly the disruption of GSK's operations in China.
While GlaxoSmithKline gets a $30 million milestone for commercializing Breo Ellipta, drug partner Theravance stands to gain royalties on sales of the COPD drug. Read more about the drug.
GlaxoSmithKline and the Bill and Melinda Gates Foundation are joining forces to develop vaccines that stand up better in the heat, making them easier to deploy in developing world. Read more about the effort.
Ginny Rometty is No. 1 and GSK's Dierdre Connelly is No. 30 on the latest list of the "Most Powerful Women" in business from Fortune. Meanwhile, Duke's new CEO premiers at No. 16.